This inventor holds 3 USPTO granted patents. Top assignee: Bayer Corporation. Active years: 1999-2002.
Location History:
- Walnut Creek, CA (US) (1999 - 2002)
- Alamo, CA (US) (2002)
Company Filing History:
Years Active: 1999-2002
Title: Innovations of Robert Gundel in T-Cell Selective Interleukin-4 Agonists
Introduction
Robert Gundel is an accomplished inventor based in Walnut Creek, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of interleukin-4 agonists. With a total of 3 patents to his name, Gundel's work focuses on enhancing therapeutic applications while minimizing toxicity.
Latest Patents
Gundel's latest patents include innovations related to polynucleotides encoding T-cell selective interleukin-4 agonists. His inventions are directed towards human IL-4 muteins that exhibit T cell activating activity while reducing endothelial cell activating activity. Specifically, these muteins are designed to promote T cell proliferation and decrease IL-6 secretion from HUVECs compared to wild-type IL-4. This advancement allows for a less toxic IL-4 mutant, enhancing its therapeutic potential. The patents also encompass polynucleotides coding for these muteins, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions, and therapeutic methods of treatment.
Career Highlights
Robert Gundel is currently associated with Bayer Corporation, where he continues to innovate in the field of biotechnology. His work has been pivotal in advancing the understanding and application of interleukin-4 in therapeutic settings.
Collaborations
Gundel has collaborated with notable colleagues, including Armen B Shanafelt and Jeffrey M Greve. These partnerships have contributed to the successful development of his patented technologies.
Conclusion
Robert Gundel's contributions to the field of biotechnology, particularly in the development of T-cell selective interleukin-4 agonists, highlight his innovative spirit and dedication to improving therapeutic options. His work continues to pave the way for advancements in medical treatments.